Shelf life (days): 1460.0
Formulation: A crystalline solid
Formal Name: 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide
Purity: ≥98%
Formula Markup: C10H8F2N4O
Formula Weight: 238.2
CAS Number: 106308-44-5
Notes: Lennox-Gastaut syndrome (LGS) is a severe pediatric epilepsy syndrome characterized by multiple seizure types.{30562} Rufinamide is an anticonvulsant.{58372} It inhibits the activation of voltage-gated sodium channel 1.1 (Nav1.1) when used at a concentration of 100 µM.{58370} Rufinamide inhibits Nav1.1, but not Nav1.2, Nav1.3, and Nav1.6, opening and increases the action potential threshold in primary rat hippocampal neurons. It is an inhibitor of carbonic anhydrase VA (CAVA; Ki = 343.8 nM) that is selective for CAVA over CAI and CAII (Kis = >10,000 nM for both).{58371} Rufinamide (100 µM) prolongs the preictal phase and reduces seizure-like event frequency in an in vitro model of epileptiform activity in rat hippocampal slices.{58369} It inhibits seizures induced by pentylenetetrazole (Item No. 18682) in a mouse model of epilepsy (ED50 = 54 mg/kg, i.p.) and reduces kainic acid-induced neuronal cell death in the mouse hippocampal CA3 region when used at doses of 25, 50, and 100 mg/kg.{58368,58367} Formulations containing rufinamide have been used in the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS).
English
Deutsch
